Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06211335 | Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 24 | University of California, DavisOTHER | 1 | Mar 12, 2026 |
| clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07035249 | DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 9 | West China HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07456878 | Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06171750 | Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors(ANCHOR) | recruiting | Phase 1 | 97 | Ankyra Therapeutics, IncINDUSTRY | 2 | Mar 6, 2026 | clinicaltrials |
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | recruiting | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04900818 | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 330 | I-Mab Biopharma US LimitedINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT05901545 | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer | recruiting | Phase 1 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05526924 | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer | recruiting | Phase 1 | 30 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07444281 | An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer | recruiting | Phase 1 | 24 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07150546 | Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. | recruiting | Phase 1 | 15 | Emory UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07441174 | IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | recruiting | Phase 1 | 80 | ProteinQure Inc.INDUSTRY | 2 | Feb 23, 2026 | clinicaltrials |
| NCT05488522 | SBRT With Atezo/Bev for HCC | recruiting | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06384560 | Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)(PREOPANC-5) | recruiting | Phase 1 / Phase 2 | 66 | Amsterdam UMC, location VUmcOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | recruiting | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 42 | Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06623396 | A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07107490 | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | recruiting | Phase 1 | 122 | Chugai PharmaceuticalINDUSTRY | 3 | Feb 6, 2026 | clinicaltrials |
| NCT07391839 | MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 40 | Suzhou Mednovo Yi Medical Technology Co., Ltd.OTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05504707 | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer(DecipHER) | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07385001 | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | recruiting | Phase 1 / Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | recruiting | Phase 1 / Phase 2 | 72 | Theravectys S.A.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07030283 | Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis | recruiting | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 100 | Gilead SciencesINDUSTRY | 3 | Jan 30, 2026 | clinicaltrials |
| NCT04150042 | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells(SHARON) | recruiting | Phase 1 | 24 | General Oncology, Inc.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05542407 | ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer | recruiting | Phase 1 | 58 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05085496 | Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05556473 | F-Tryptophan PET/CT in Human Cancers | recruiting | Phase 1 | 24 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | recruiting | Phase 1 | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07359417 | MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma(ESCALATE) | recruiting | Phase 1 | 30 | UMC UtrechtOTHER | 1 | Jan 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2026source: clinicaltrials